Abeona Therapeutics (ABEO) Projected to Post Earnings on Monday

Abeona Therapeutics (NASDAQ:ABEO) is expected to be releasing its earnings data before the market opens on Monday, March 17th. Analysts expect Abeona Therapeutics to post earnings of ($0.35) per share and revenue of $0.10 million for the quarter.

Abeona Therapeutics Stock Performance

ABEO opened at $5.16 on Monday. The stock has a market cap of $224.31 million, a P/E ratio of -1.92 and a beta of 1.79. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The stock’s 50 day simple moving average is $5.56 and its 200 day simple moving average is $5.85. Abeona Therapeutics has a 1-year low of $3.05 and a 1-year high of $8.87.

Analysts Set New Price Targets

ABEO has been the topic of a number of recent research reports. StockNews.com lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 22nd. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a research note on Wednesday, February 19th. Finally, Oppenheimer assumed coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They set an “outperform” rating and a $16.00 price objective for the company. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $17.50.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.